Position of the Transparency Council – Doptelet (avatrombopag)

At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 48/2022 on the evaluation of Doptelet (avatrombopag) under the drug programme: “Treatment of adult patients with primary immune thrombocytopenic purpura (ICD-10: D69.3)”.

Publication in Public Information Bulletin (BIP)